Jefferies initiated coverage of Lumexa Imaging (LMRI) with a Buy rating and $23 price target The company is well positioned for 8%-9% EBITDA growth annually over the next five years, the analyst tells investors in a research note. The firm believes Lumexa will benefit from secular tailwinds in imaging, the opening of new clinics, the ramp of facilities opened in the last few years, and rate growth.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMRI:
- Lumexa Imaging Holdings: Leveraging Outpatient Growth and JV Model to Drive Premium-Valued Expansion and Deleveraging Upside
- Lumexa Imaging Secures New Long-Term Senior Credit Facilities
- Opening Day: SpaceX confirms 2026 IPO plans
- Lumexa Imaging Holdings Completes Successful IPO
- Lumexa Imaging opens at $18.65, IPO priced at $18.50 per share